HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharmacists’ Regard Grows For OTCs As Rx Alternatives, APhA Officer Says

This article was originally published in The Tan Sheet

Executive Summary

Both pharmacists and consumers are paying increasing attention to the use of some OTCs as a solution to the Medicare Part D "coverage gap," according to Timothy L. Tucker, president-elect of the American Pharmacists Association

You may also be interested in...



FDA Plans Behind-The-Counter Drugs Meeting, Mulls “Transitional” Status

FDA will discuss the idea of behind-the-counter drug sales as a possible transitional stage between Rx and OTC status when it holds a forum on the topic with stakeholders

Expensive Rx Drugs Put Spotlight On OTC Opportunity – Economist

Over-the-counter drug firms have a promising opportunity to market their products as alternatives to Rx drugs for consumers confronted with coverage gaps in Medicare Part D and private insurance plans, a Princeton University economics and public affairs professor advised industry executives

Plan B Pioneers OTC “Pharmacy Counter” Approval, Dual-Status Marketing

FDA's decision to approve emergency contraceptive Plan B for over-the-counter sale to women age 18 and older cracks open the door on a pharmacy-only, behind-the-counter model for nonprescription drug sales

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS137975

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel